Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

This study is testing a new combination regimen — etoposide, cytarabine, and a long-acting growth factor (PEG-rhG-CSF) — to stimulate stem cell production in the blood before a stem cell transplant. This process, called mobilization, is a necessary step before transplant for blood cancer patients, and researchers are evaluating whether this combination is safe and effective. **You may be eligible if:** - You have lymphoma or multiple myeloma and are a candidate for an autologous (using your own) stem cell transplant - Your general health is good enough for the procedure (ECOG score 0–2) - Your life expectancy is at least 3 months - You understand the study and are willing to participate **You may NOT be eligible if:** - You have serious heart, liver, or kidney problems - You have previously undergone stem cell mobilization - You have active infections or uncontrolled medical conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.